DHR Stock Recent News
DHR LATEST HEADLINES
The latest trading day saw Danaher (DHR) settling at $230.81, representing a -1.7% change from its previous close.
WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Danaher has undergone a radical transformation from a real estate trust to a leader in the life sciences industry through strategic acquisitions. The company's focus on continuous improvement and efficiency, guided by the Kaizen philosophy, has been a driving force behind its success. Danaher's recent divestments and increased focus on its core businesses have led to strong financial performance and growth, making it an attractive investment option.
Danaher is my low-risk SWAN stock pick for 2024, with a strong track record of growth and a focus on rational, data-driven decision-making at its core. The end market for Danaher's healthcare and bioprocessing products is expected to return to growth, driven by new technology and increased funding. The spin-off of certain segments and potential future acquisitions, as well as operational improvements and new growth opportunities for Danaher, should increase cash flows over time.
WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.
Strength in the Life Sciences segment and accretive acquisition bode well for Danaher (DHR). The company's measures to reward its shareholders are encouraging.
Danaher (DHR) closed the most recent trading day at $226.45, moving -0.34% from the previous trading session.
Danaher (DHR) concluded the recent trading session at $221.35, signifying a +1.77% move from its prior day's close.
Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.